These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 9440663)

  • 21. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols.
    Gable CB; Tierce JC; Simison D; Ward D; Motte K
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):413-20. PubMed ID: 8673552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.
    Scharfstein JA; Paltiel AD; Freedberg KA
    Med Decis Making; 1997; 17(4):373-81. PubMed ID: 9343795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.
    Cheever LW; Chaisson RE; Gallant JE
    West J Med; 1996; 165(1-2):67-73. PubMed ID: 8855697
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
    Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
    N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PHS guidelines map out prevention routes through terrain of infections. Public Health Service.
    AIDS Alert; 1995 Sep; 10(9):109-11. PubMed ID: 11362773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis of opportunistic infections in HIV/AIDS.
    Goldschmidt RH
    Am Fam Physician; 1997 Sep; 56(4):1039-40. PubMed ID: 9310055
    [No Abstract]   [Full Text] [Related]  

  • 28. HIV: prevention of opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2005 Jun; (13):834-53. PubMed ID: 16135281
    [No Abstract]   [Full Text] [Related]  

  • 29. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.
    Asch SM; Gifford AL; Bozzette SA; Turner B; Mathews WC; Kuromiya K; Cunningham W; Andersen R; Shapiro M; Rastegar A; McCutchan JA
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):340-4. PubMed ID: 11707670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
    Rose DN; Sacks HS
    AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping preventive treatments.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jul; 12(7):9-10. PubMed ID: 11367080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of prophylaxis for opportunistic infections in HIV-infected patients.
    Decker CF; Masur H
    AIDS; 1994 Jan; 8(1):11-20. PubMed ID: 8011221
    [No Abstract]   [Full Text] [Related]  

  • 34. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
    Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
    Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
    Freedberg KA; Tosteson AN; Cohen CJ; Cotton DJ
    J Acquir Immune Defic Syndr (1988); 1991; 4(5):521-31. PubMed ID: 1673157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis for opportunistic infections in patients with HIV infection.
    Gallant JE; Moore RD; Chaisson RE
    Ann Intern Med; 1994 Jun; 120(11):932-44. PubMed ID: 8172439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
    Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.